Table 2.

Baseline Characteristics of ACS and Chronic IHD Patients, Receiving and Not Receiving Aspirin Treatment

Variable	ACS Patients			P Value*	IHD Patients			P Value*
	Not Receiving Aspirin, n=16	P Value	Receiving Aspirin, n=47		Receiving Aspirin, n=49	P Value	Not Receiving Aspirin, n=19
Male sex, n (%)	13 (81.3)	0.870	39 (83)	<0.001	21 (42.9)	0.292	11 (57.9)	0.167
Age, y	68 (55 to 71)	0.960	66 (61 to 74)	0.626	69 (63 to 77)	0.989	68 (63 to 80)	0.515
BMI, kg/m²	26 (25 to 26)	0.920	27 (24 to 30)	1.000	26 (24 to 29)	0.995	26 (24 to 29)	0.996
Smoking, n (%)	6 (37.5)	0.762	15 (31.9)	0.491	11 (22.4)	0.742	3 (15.7)	0.433
Hypertension, n (%)	7 (43.8)	0.027	36 (76.6)	0.622	39 (79.5)	1.000	15 (78.9)	0.300
Systolic blood pressure, mm Hg	120 (120 to 140)	0.661	140 (123 to 140)	1.000	130 (125 to 140)	0.988	140 (130 to 143)	0.647
Diastolic blood pressure, mm Hg	75 (60 to 80)	0.914	80 (70 to 83)	0.738	80 (71 to 85)	0.974	80 (75 to 90)	0.524
Diabetes, n (%)	3 (18.8)	0.740	13 (27.7)	0.135	21 (42.8)	0.020	2 (10.5)	0.656
Hypercholesterolemia, n (%)	9 (56.3)	0.546	31 (65.9)	0.824	35 (71.4)	0.048	8 (42.1)	0.505
Fasting plasma glucose, mmol/L	4.89 (4.39 to 6.61)	0.393	5.94 (5 to 6.89)	0.805	5.72 (4.83 to 6.61)	0.429	5.22 (4.72 to 5.33)	0.991
Total cholesterol, mmol/L	4.26 (3.93 to 5.89)	1.000	4.6 (4.01 to 5.27)	0.989	4.7 (4.19 to 5.25)	0.992	4.63 (3.9 to 5.09)	0.961
HDL cholesterol, mmol/L	1.27 (0.85 to 1.34)	1.000	1.16 (0.96 to 1.32)	0.311	1.24 (1.09 to 1.47)	0.795	1.21 (0.98 to 1.37)	0.988
Triglyceride, mmol/L	1.86 (0.89 to 2.44)	0.689	1.58 (1.33 to 1.77)	0.930	1.68 (1.23 to 1.87)	0.531	1.31 (0.85 to 1.78)	0.357
LDL cholesterol, mmol/L	2.97 (2.4 to 4.03)	0.939	2.71 (2.22 to 3.33)	0.985	3.1 (2.66 to 3.41)	0.826	2.97 (1.94 to 3.39)	0.779
Hemoglobin, 109/L	16 (15 to 16)	0.695	14 (13 to 15)	0.981	14 (12 to 16)	0.859	14.9 (13.5 to 15.5)	0.946
Red blood cells, 109/L	4.89 (4.8 to 4.9)	0.934	4.6 (4.2 to 5.1)	1.000	4.6 (4.4 to 4.9)	0.918	4.91 (4.7 to 5.1)	1.000
White blood cells, 109/L	8 (5 to 10)	0.993	7 (6 to 11)	1.000	8 (6 to 9)	0.936	6.8 (5.8 to 8.1)	0.994
Platelet count, 109/L	188 (165 to 210)	0.953	220 (156 to 273)	0.976	230 (196 to 262)	0.924	197 (141 to 261)	0.997
Previous MI or revascularization, n (%)	9 (56.3)	0.778	24 (51.1)	0.838	23 (46.9)	<0.001	0 (0)	<0.001
No. of diseased vessels, mean±SD	1.67±0.97	0.799	1.61±0.94	0.650	1.48±1.08	0.677	1.29±1.25	0.407
TIMI risk score, n (%)
Low	9 (56.3)	0.900	10 (21.3)	—	—	—	—	—
Intermediate	6 (37.5)	0.140	22 (46.8)	—	—	—	—	—
High	1 (6.3)	0.857	15 (31.9)	—	—	—	—	—
Medical treatment, n (%)
Clopidogrel	7 (43.7)	0.034	35 (74.4)	<0.001	4 (8.2)	0.570	1 (5.3)	0.013
Lipid‐lowering drugs	8 (50)	0.650	35 (74.4)	0.190	31 (63.3)	0.172	8 (42.1)	0.740
ACE inhibitors or ARBs	8 (50.0)	1.000	23 (48.9)	0.683	27 (55.1)	1.000	10 (52.6)	1.000
β‐Blockers	4 (25)	0.142	23 (48.9)	1.000	24 (49)	0.787	8 (42.1)	0.476
Digitalis	0 (0)	0 (0)	0 (0)	1.000	1 (2)	0.484	1 (5.3)	1.000
Calcium channel antagonists	2 (12.5)	1.000	8 (17)	0.014	1 (2)	1.000	0 (0)	0.202
Nitrates	0 (0)	0.322	6 (12.7)	0.051	1 (2)	1.000	0 (0)	—
Diuretics	1 (6.3)	0.668	7 (14.9)	0.315	12 (24.5)	0.555	6 (31.6)	0.096
PPI	2 (12.5)	0.714	10 (21.3)	0.014	2 (4.1)	0.310	2 (10.5)	1.000

Values are n (%) or median (Q₁ to Q₃).The χ² or Fisher exact test was used for comparison of categorical data, when appropriate. ANOVA with the Scheffè post‐hoc test to correct for multiple comparisons was used for comparison of continuous variables. ACS, acute coronary syndrome; BMI, body mass index; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; MI, myocardial infarction; ACE, angiotensin‐converting enzyme; IHD, ischemic heart disease; ARB, angiotensin II receptor blocker; PPI, proton pump inhibitor.

^*P value for comparison between ACS and IHD patients receiving aspirin.

^*P value for comparison between ACS and IHD patients not receiving aspirin.